OXiGENE tests CA4P for macular disease

Waltham, MA-OxiGENE Inc., a clinical-stage biopharmaceutical company developing novel therapies to treat eye diseases and cancer, is now focusing its ophthalmology strategy on oral or other non-intravitreal forms of administration of Combretastatin A4 Phosphate (CA4P) for age-related macular degeneration.

Waltham, MA-OxiGENE Inc., a clinical-stage biopharmaceutical company developing novel therapies to treat eye diseases and cancer, is now focusing its ophthalmology strategy on oral or other non-intravitreal forms of administration of Combretastatin A4 Phosphate (CA4P) for age-related macular degeneration.

The company also is studying CA4P for myopic macular degeneration (MMD-213), recently closing enrollment in a phase II clinical trial with 22 of the previously planned 36 patients enrolled. The last of the enrolled patients are expected to complete this trial by the end of the year.

The masked, parallel-group, dose-ranging, multicenter trial is evaluating the safety and efficacy of three doses (27, 36, and 45 mg/m2 ) of CA4P for the treatment of subfoveal choroidal neovascularization in patients with pathologic myopia. The company expects to announce results in the first quarter of 2007.